Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, van de Wetering G, Davids MS. Chatterjee A, et al. Among authors: ravelo a. J Manag Care Spec Pharm. 2021 Nov;27(11):1532-1544. doi: 10.18553/jmcp.2021.27.11.1532. J Manag Care Spec Pharm. 2021. PMID: 34714110 Free PMC article.
The model estimated life-years gained, quality-adjusted life-years (QALYs) gained, and costs. The time horizon was 20 years, with a cycle time of 28 days. Outcomes and costs were discounted at 3.0% per year, and costs were estimated from a US health care payer persp …
The model estimated life-years gained, quality-adjusted life-years (QALYs) gained, and costs. The time horizon was 20 years, with a c …
[No title available]
[No authors listed] [No authors listed] PMID: 36163891
Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
Shah-Manek B, Wong W, Ravelo A, DiBonaventura M. Shah-Manek B, et al. Among authors: ravelo a. J Manag Care Spec Pharm. 2018 Jun;24(6):565-571. doi: 10.18553/jmcp.2018.17449. Epub 2018 Feb 16. J Manag Care Spec Pharm. 2018. PMID: 29451078 Free PMC article.
Oncologists estimated the mean monthly OOP costs for patients with insurance to range from $1,260 for a new oral medication to $1,700 for a new infused medication. Only 26% of oncologists were comfortable or very comfortable with rating costs associated with afforda …
Oncologists estimated the mean monthly OOP costs for patients with insurance to range from $1,260 for a new oral medication to $1,700 …
Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.
Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS. Walker MS, et al. Among authors: ravelo a. Health Qual Life Outcomes. 2017 Aug 14;15(1):160. doi: 10.1186/s12955-017-0735-4. Health Qual Life Outcomes. 2017. PMID: 28806963 Free PMC article.
160 results